RSS Feeds
Search

Companies

Zambon Company SpA

Zambon Company SpA
Zambon Company SpA is a privately-held multinational pharmaceutical and chemical company that looks for in-licensing products in late stage development or already in the market..

The company in detail

Profile

Zambon Company SpA is a pharmaceutical and chemical company founded in 1906, with headquarter in Bresso (Milan), Italy. It operates directly in North and South America, Europe and Asia, with over 2,500 employees in 15 Countries and consolidated sales of 555M€ in 2008, 80% of which generated by Zambon Pharmaceuticals SpA. Zambon Pharmaceuticals SpA leading products are Fluimucil (N-Acetylcysteine); Monuril (Fosfomycin tromethamol); Spidifen (Ibuprofen arginine). Main therapeutic areas of interest for Zambon Pharmaceuticals SpA are Respiratory, Women's care and pain relief, with focus on mild-moderate diseases. The Company is developing a portfolio of product ranging from ethical prescription drugs to self-medication products. Zambon Pharmaceuticals SpA has production plants based in EU and China.

Partnering strategy/interests

Zambon's Pharmaceuticals Corporate Licensing Department is actively looking for in-licensing of products in the Respiratory, Woman's care and Pain relief. Moreover, Zambon Pharmaceuticals SpA is looking for out-licensing core products in territories where the Company is not present with Affiliates. Zambon's current strategy is to develop a portfolio of products ranging from ethical prescription drugs to OTC products that can play a significant role in the target areas. Main medical target currently visited are: GPs, Gynaecologists, ENT, Pediatricians, Pneumologists and Pharmacies, the latter covered by specialized sales lines in all key Countries.

In-licensing

Respiratory; women's care; dermatology; pain relief; GI More
NCEs for innovative therapeutic targets in inflammatory/immunologic diseases. More

R&D

To view this information, you must subscribe to Pharmalicensing Intelligence.

Partnerships

To view this information, you must subscribe to Pharmalicensing Intelligence.

Deals

To view this information, you must subscribe to Pharmalicensing Intelligence.

Press Releases

(20th Jul 2005) A strategic alliance which will strengthen the Italian chemical and Pharmaceutical company in the Asiatic and international market is sealed Today in Ahmedabad (India) More
(1st Jun 2005) Zambon Group S.p.A. and ObeTherapy Biotechnology jointly announced today that they have achieved the first milestone in their R&D collaboration agreement More
(14th Jan 2003) Zambon Group S.p.A. and Access Pharmaceuticals Inc. have announced the signing Licensing Agreement granting Zambon Group the marketing rights for amlexanox for the treatment of canker sores. More
(6th Jun 2002) Zambon will license Vectura's PowderHale(tm) pulmonary formulation technology for the development and commercialisation of a new dry powder inhaler product. More
(4th Apr 2002) Zambon and Fournier signed a license agreement for the development of new chemical entities from Fournier's know-how and patents on Interleukin-4 (IL-4) antagonists and Interleukin-4/Interleukin-5 (IL-4/IL-5) secretion inhibitors More
(12th Feb 2002) Zambon and APR Applied Pharma Research S.A. have signed an international license agreement for the further development of innovative patented products in matrix patch form More
More press releases

Senior management

To view this information, you must subscribe to Pharmalicensing Intelligence.

Contact details

Tony Maggi
Head
Business Development & Licensing

Contact directly

Full contact list

Head office

Zambon Company SpA
Via Lillo del Duca 10
20091 Bresso
Milano
20091
Italy

Company figures

Formed: 1906
Annual Turnover: 562 million (2011)
Number of employees: 2652

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us